Company Name, Ticker, Competitors, else..

Genprex Inc (NASDAQ: GNPX)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Genprex Inc 's

Name: Genprex Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GNPX Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Genprex Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 56.56 %, recorded in the same quarter.

• List of GNPX Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Genprex Inc recorded a net loss, as well as most of its competitors.

<< GNPX Stock Performance Comparisons

Genprex Inc 's Comment on Competition and Industry Peers

The company utilizes patents, regulatory exclusivity, data exclusivity, market exclusivity, orphan drug designation, and patent term extensions to protect its gene therapy technologies. It has developed and in-licensed multiple patents and pending applications related to compositions-of-matter, methods-of-use, and other technologies. The company holds a worldwide, exclusive license from MD Anderson to patents covering therapeutic use. MD Anderson is identified as a competitor in its filings.

<< See the full list of GNPX competitors

*Market share is calculated based on total revenue.

GNPX's Stock Performance relative to its Competitors

Publicly Traded Peers of Genprex Inc

Iovance Biotherapeutics inc
Share Performance

+160.42%

This Quarter

Iovance Biotherapeutics inc

Profile

Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.

More about Iovance Biotherapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 4,724.734 mill.	$ 324.969 mill.	$ -289.517 mill.

Novabridge Biosciences
Share Performance

+10.79%

This Quarter

Novabridge Biosciences

Profile

The company develops drug candidates and conducts related research and development activities in China.

More about Novabridge Biosciences's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 155.963 mill.	$ - mill.	$ -88.340 mill.

Neurogene Inc
Share Performance

-8.23%

30 Days

Neurogene Inc

Profile

The company develops genetic medicines targeting rare neurological diseases and is currently in clinical stages.

More about Neurogene Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 738.241 mill.	$ - mill.	$ -111.110 mill.

Nkarta Inc
Share Performance

+0.73%

This Quarter

Nkarta Inc

Profile

Nkarta Inc is a biotechnology company with a business model centered on developing and commercializing engineered natural killer (NK) cell therapies for cancer patients. By utilizing proprietary technologies and expertise in genetic engineering, the company aims to enhance the therapeutic potential of NK cells and address unmet needs in the field of oncology. Nkarta Inc focuses on research, development, and production of these advanced cell therapies, collaborating with partners and regulators to bring innovative treatments to patients.

More about Nkarta Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 205.606 mill.	$ - mill.	$ -117.324 mill.

Nurix Therapeutics Inc
Share Performance

-0.93%

Over The Past 5 Days

Nurix Therapeutics Inc

Profile

Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.

More about Nurix Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,840.429 mill.	$ 36.766 mill.	$ -341.351 mill.

61 more competitors available

Sources: Genprex Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Sunday, September 13, 2026 11:36 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Genprex Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.